These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18249369)

  • 1. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
    Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome.
    Rabinson J; Meltcer S; Zohav E; Gemer O; Anteby EY; Orvieto R
    Fertil Steril; 2008 Feb; 89(2):472-4. PubMed ID: 17582402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.
    Bjercke S; Fedorcsak P; Abyholm T; Storeng R; Ertzeid G; Oldereid N; Omland A; Tanbo T
    Hum Reprod; 2005 Sep; 20(9):2441-7. PubMed ID: 15919773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?
    Orvieto R; Meltcer S; Liberty G; Rabinson J; Anteby EY; Nahum R
    Gynecol Endocrinol; 2012 Jun; 28(6):422-4. PubMed ID: 22578028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
    Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
    Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.
    Bosch E; Escudero E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2005 Nov; 84(5):1529-32. PubMed ID: 16275263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A spontaneous luteinizing hormone surge is beneficial in women with unexplained infertility undergoing controlled ovarian hyperstimulation without in vitro fertilization.
    Costello MF; Hughes GJ; Garrett DK; Hanjani A; Steigrad SJ
    Int J Fertil Womens Med; 1998; 43(1):28-33. PubMed ID: 9532467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
    Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
    Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists.
    Rabinson J; Ashkenazi J; Homburg R; Meltcer S; Anteby EY; Orvieto R
    Fertil Steril; 2009 Apr; 91(4 Suppl):1473-5. PubMed ID: 18937940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
    Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
    Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
    Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
    Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
    Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
    Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy.
    Huirne JA; van Loenen AC; Schats R; McDonnell J; Hompes PG; Schoemaker J; Homburg R; Lambalk CB
    Hum Reprod; 2005 Feb; 20(2):359-67. PubMed ID: 15567880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.